Objective To construct a platelet membrane bionic nanoprobe targeting PLT-RAP@NPs, and explore its immune escape, targeting and adhesion ability in vitro, as well as drug delivery after combination with UTMD. Methods RAP was loaded onto polymer PLGA by single emulsification-solvent evaporation technique, and a nanoprobe RAP@NPs was synthesized. Platelet membrane vesicles extracted by density-gradient centrifugation and repeated freeze-thaw cycles were used to prepare platelet membrane-coated biomimetic nanoprobe PLT-RAP@NPs by ultrasonic oscillation method. The particle size, potential and stability of nanoprobe were detected by dynamic light scattering technique. The microscopic morphology of the nanoprobe was observed by transmission electron microscopy. High-performance liquid chromatography was used to detect the encapsulation efficiency and drug loading efficiency of RAP in various proportions of nanoprobe to determine the best drug-loading protocol for RAP. DiI dye was encapsulated into PLGA to form DiI@PLGA and PLT-DiI@PLGA instead of the RAP@NPs and PLT-RAP@NPs for fluorescence detection, and then the NPs were co-incubated with RAW264.7 macrophages, foam cells, and endothelial cells in vitro. The phagocytosis and adhesion of these cells to the NPs were observed and analyzed by fluorescence microscope. For evaluating cell proliferation and cytotoxicity, CCK8 was used to evaluate the cell viability. In vitro dialysis and high-performance liquid chromatography were used to evaluate RAP release of PLT-RAP@NPs combined with UTMD. Results PLT-RAP@NPs were transparent and spherical, and showed a uniform size and clear core-shell structure. The surface of the core was coated with a film. The drug encapsulation efficiency reached the highest when 100 mg PLGA and 3 mg RAP entered the organic solvent; the encapsulation and drug loading efficiency were 60.35% and 2.18%, respectively. After RAW264.7 cells were co-incubated with DiI@PLGA and PLT-DiI@PLGA separately for 2 h, the orange-red fluorescence intensity of the DiI@PLGA group was significantly higher than that of the PLT-DiI@PLGA group, while the opposite result was obtained when the foam cells were co-incubated with the NPs. After TNF-α stimulated HUVEC up-regulated the expression of von Willebrand factor (vWF) and then co-incubated with the NPs for 2 h, a significant overlap between orange-red and green fluorescence in the PLT-DiI@PLGA group was shown, while no significant overlap was displayed in the DiI@PLGA group. With the increase of RAP concentration, the cell viability of the free RAP group gradually decreased, while the cell proliferation was less affected in PLT-RAP@NPs group. Slow release of RAP in RAP@NPs and PLT-RAP@NPs was shown, the release percentage was 42.12 % and 33.74 % at 72 h, and were raised to 75.57 % and 67.54 % after combination with UTMD, respectively. Conclusions The successfully prepared platelet membrane bionic nanoprobe PLT-RAP@NPs can inhibit macrophage phagocytosis, enhance foam cell uptake and improve endothelial cell adhesion through the biological function of platelet membrane, so as to achieve immune escape and targeting ability. Combined with UTMD, RAP controlled release of targeted can be realized.